Search
AstraZeneca Faces Potential $8 Million Fine in China Over Breast Cancer Drug Tax Issue
2025-04-30 /
Read about 0 minute
Author：小编
On April 29th, local time in the UK, AstraZeneca disclosed during its latest earnings conference that the company might incur an additional fine of $8 million in China due to unpaid taxes on the imported breast cancer drug Enhertu. Previously, AstraZeneca had already faced a maximum penalty of $4.5 million for similar tax evasion on two other cancer drugs, Imfinzi and Imjudo.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
